Metagen Therapeutics is developing Japan’s first ‘intestinal microbiota bank’ in order to effectively implement FMT procedures nation-wide, and for the research and development of microbiome therapeutics.

The human microbiome is comprised of bacterial flora found throughout the human body, including in the intestines, skin, and oral cavity. Intestinal microbiome in particular, has a complex and dynamic population of microorganisms. In recent years, research on the intestinal flora has made significant progress and its symbiotic relationship with various diseases such as cancer, ulcerative colitis, Parkinson’s disease, and allergies, has become clear.

FMT and its research has been shown to be a safe and efficacious treatment around the world, and microbiome drug discovery is being actively carried out.